TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18021825

Group type: COMPARATOR
Intervention: Composite resin (Z100 MP) (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cobalt‐chromium ceramic alloy custom‐made cast post and core (IPS d.SIGN 30; CCPC group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carbon fiber post system (Tech Xop 2000; CFP group)
Number of subjects: 40
Study: 16055396

Group type: EXPERIMENTAL
Intervention: Autofluorescence bronchoscopy (AF)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: White-light bronchoscopy (WL) combined with p53 analysis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of WL, AF, and p53 mutation analysis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Histopathology
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All methods (WL, AF, p53)
Number of subjects: 36
Study: 12383074

Group type: EXPERIMENTAL
Intervention: Maximal strength training (three times a week for 8 weeks, using a cable pulley at 85% of one repetition maximum)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Maximal strength training
Number of subjects: 19
Study: 10193106

Group type: EXPERIMENTAL
Intervention: Experimental blackcurrant juice drink with calcium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 8788691

Group type: EXPERIMENTAL
Intervention: Behavioral skills training
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 12-Step recovery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Men in the same sample
Number of subjects: 31
Study: 1688065

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and procaterol (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and procaterol (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 80
Study: 6119777

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ranitidine after initial treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ranitidine after initial placebo treatment
Number of subjects: 50
Study: 31358470

Group type: EXPERIMENTAL
Intervention: 4-week walking intervention aimed at increasing daily steps
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Days with higher than average activity
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Low-impact physical activity (walking)
Number of subjects: 59
Study: 28394081

Group type: EXPERIMENTAL
Intervention: SRP+LLLT (non-smokers with chronic periodontitis)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP+Sham (non-smokers with chronic periodontitis)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP+LLLT (smokers with chronic periodontitis)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP+Sham (smokers with chronic periodontitis)
Number of subjects: 30
Study: 26415995

Group type: EXPERIMENTAL
Intervention: Chemotherapy with cediranib
Number of subjects: 296

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 296
Study: 23516092

Group type: EXPERIMENTAL
Intervention: Gushen Pian (double-blind treatment group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (double-blind control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gushen Pian (simple treatment group)
Number of subjects: 120
Study: 21829616

Group type: EXPERIMENTAL
Intervention: T. suis eggs (2500 eggs every 21 days for 168 days, total 8 doses)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 19230605

Group type: EXPERIMENTAL
Intervention: Observed eating school meals
Number of subjects: 555

Group type: COMPARATOR
Intervention: Not observed eating school meals
Number of subjects: 555
Study: 17965790

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 897
Study: 15491755

Group type: EXPERIMENTAL
Intervention: Precolposcopy counseling with further explanation and discussion with an experienced colposcopic nurse
Number of subjects: 220

Group type: COMPARATOR
Intervention: No further discussion (control group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Precolposcopy counseling
Number of subjects: 220
Study: 11528230

Group type: EXPERIMENTAL
Intervention: Blood flow rate (Qb) 400 ml/min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Blood flow rate (Qb) 300 ml/min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Blood flow rate (Qb) 200 ml/min
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: UM Kt/V
Number of subjects: 4
Study: 9935259

Group type: EXPERIMENTAL
Intervention: 200 mg trovafloxacin by mouth
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2 g cefoxitin by i.v. infusion
Number of subjects: 200
Study: 7923666

Group type: EXPERIMENTAL
Intervention: Sematilide
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 33
Study: 3169282

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with human menopausal gonadotropin (hMG) starting on day 2 of the cycle
Number of subjects: 173

Group type: COMPARATOR
Intervention: Ovarian stimulation with human menopausal gonadotropin (hMG) starting on day 4 of the cycle
Number of subjects: 173
Study: 31635477

Group type: EXPERIMENTAL
Intervention: HRV biofeedback (BF) intervention, 4 training sessions
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HRV biofeedback (BF) intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 35
Study: 29565660

Group type: EXPERIMENTAL
Intervention: Standard care plus Oral Health 4 Life (OH4L)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 718
Study: 28991280

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administration during internal fracture reduction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no PRP application)
Number of subjects: 20
Study: 25689258

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular rhPDGF-BB (0.2, 1.5, or 5 μg per day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular rhPDGF-BB
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23860406

Group type: EXPERIMENTAL
Intervention: Listening to unpleasant music during stress exposure
Number of subjects: 14

Group type: COMPARATOR
Intervention: Listening to pleasant music during stress exposure
Number of subjects: 14
Study: 20634303

Group type: EXPERIMENTAL
Intervention: VBM-DARTEL
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional VBM
Number of subjects: 134

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 134
Study: 17970838

Group type: EXPERIMENTAL
Intervention: Methylene blue-directed biopsies (MB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional four-quadrant biopsies (4QB)
Number of subjects: 48
Study: 15982790

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR live oral cholera vaccine
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 12852707

Group type: EXPERIMENTAL
Intervention: Fluvastatin ER 80 mg QD
Number of subjects: 173

Group type: COMPARATOR
Intervention: Fluvastatin IR 40 mg QD
Number of subjects: 173
Study: 10665628

Group type: EXPERIMENTAL
Intervention: Citalopram 10 mg/day
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Citalopram 60 mg/day
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study: 8604406

Group type: EXPERIMENTAL
Intervention: 3-day course of trimethoprim-sulfamethoxazole (Bactrim, Cotrim, Septra)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-day course of trimethoprim alone (Proloprim, Trimpex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous antimicrobial prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of catheter-related infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 to 6 weeks of therapy for infection in men
Number of subjects: 0
Study: 1931469

Group type: EXPERIMENTAL
Intervention: CGRP (human alpha-CGRP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Prostacyclin (PGI2)
Number of subjects: 6
Study: 121636

Group type: EXPERIMENTAL
Intervention: Methohexitone and halothane
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Flunitrazepam, IPPV, adequate analgesia and anaesthesia
Number of subjects: 79
Study: 30980608

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 79288

Group type: EXPERIMENTAL
Intervention: RAS blockers
Number of subjects: 79288

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 79288

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 79288
Study: 28095795

Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium sulfate (50 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (Control group)
Number of subjects: 60
Study: 25875257

Group type: EXPERIMENTAL
Intervention: Aerosolized vaccine
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Subcutaneous vaccine
Number of subjects: 2004
Study: 23498346

Group type: EXPERIMENTAL
Intervention: Soy milk consumption
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cow's milk consumption
Number of subjects: 29
Study: 20521852

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wakefulness
Number of subjects: 0
Study: 19728561

Group type: EXPERIMENTAL
Intervention: Test formulation of fexofenadine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation of fexofenadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Test and Reference formulations
Number of subjects: 12
Study: 17019564

Group type: EXPERIMENTAL
Intervention: Risperidone treatment for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DIP group (6 out of 8 symptomatic for PS at baseline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NoDIP group (2 out of 12 symptomatic for PS at baseline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DIP group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NoDIP group
Number of subjects: 20
Study: 15176652

Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate extended-release capsule
Number of subjects: 24

Group type: COMPARATOR
Intervention: 20 mg methylphenidate extended-release capsule (reference treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 30 mg methylphenidate extended-release capsule
Number of subjects: 24
Study: 11563193

Group type: EXPERIMENTAL
Intervention: Dan Shao Tang and western medicine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 132
Study: 9521953

Group type: EXPERIMENTAL
Intervention: hGH treatment (mean dose 0.78 ± 0.12 IU/kg/week, subcutaneously 5 to 7 times per week for 2.2 ± 1.2 years)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 123
Study: 8039024

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (anaesthesia of the nose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Allergen challenge (without nasal anaesthesia)
Number of subjects: 10
Study: 2930092

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg of caffeine sodium benzoate)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (97% caffeine-free coffee)
Number of subjects: 13
Study: 4151126

Group type: EXPERIMENTAL
Intervention: Nicergolin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine
Number of subjects: 30
Study: 31958442

Group type: EXPERIMENTAL
Intervention: Unilateral phrenic nerve stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low flow oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive servo ventilation (ASV)
Number of subjects: 0
Study: 30901061

Group type: EXPERIMENTAL
Intervention: Purpuragenic PDL
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Multiplexed PDL/Nd:YAG
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 27
Study: 28555052

Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant (NZBC) extract (600 mg∙day‐1 CurraNZ™)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 13
Study: 25485658

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program for 8 weeks with an additional 10-month maintenance period
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study: 23916915

Group type: EXPERIMENTAL
Intervention: Telephone-delivered behavioral intervention for diabetes and hypertension
Number of subjects: 377

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 377
Study: 21951520

Group type: EXPERIMENTAL
Intervention: Physical Activity Enjoyment Scale (PACES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shortened, 8-item version of PACES
Number of subjects: 0
Study: 19233881

Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 200
Study: 17471830

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 15136103

Group type: EXPERIMENTAL
Intervention: Group 1: 200 microL of air in the syringe, 100-125 microL of air in the proximal part of the catheter, 20-25 microL of medium containing the embryos, and 10 microL of air at the tip of the catheter
Number of subjects: 102

Group type: COMPARATOR
Intervention: Group 2: Syringe and entire catheter filled with medium, embryo-containing medium aspirated without air spaces
Number of subjects: 102
Study: 11797269

Group type: EXPERIMENTAL
Intervention: Chemotherapy (standard treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of epirubicin-cisplatin-continuous 5FU (ECF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radio-chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5FU alone, 5FU-cisplatin, or 5FU-mitomycin (as preoperative or exclusive treatment)
Number of subjects: 0
Study: 9564481

Group type: EXPERIMENTAL
Intervention: Pyronaridine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 88
Study: 7817618

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol once daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 20 mg lisinopril once daily
Number of subjects: 22
Study: 3140739

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pancrease (control)
Number of subjects: 22
Study: 30836363

Group type: EXPERIMENTAL
Intervention: 15 mg lycopene, 5.8 mg phytoene and phytofluene, 0.8 mg β-carotene, 5.6 mg tocopherols from tomato extract, and 4 mg carnosic acid from rosemary extract per day
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo made from medium-chain triglycerides
Number of subjects: 149
Study: 29179974

Group type: EXPERIMENTAL
Intervention: Insulin glargine 100 units/mL (Gla-100)
Number of subjects: 3586
Study: 26807534

Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning (RIC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: RIC
Number of subjects: 128
Study: 25098959

Group type: EXPERIMENTAL
Intervention: Falls Management Exercise (FaME) programme
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP)
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1256
Study: 22054660

Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 0
Study: 19901144

Group type: EXPERIMENTAL
Intervention: Interactive computerized information (ICI)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard institutional verbal and written information (SI)
Number of subjects: 135
Study: 17264106

Group type: EXPERIMENTAL
Intervention: Immediate treatment group (4-session weekly caregiver programme)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 39
Study: 16226510

Group type: EXPERIMENTAL
Intervention: 7.5 IU ovine hyaluronidase
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: 55 IU ovine hyaluronidase
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: 75 IU ovine hyaluronidase
Number of subjects: 1362

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1362
Study: 12077736

Group type: EXPERIMENTAL
Intervention: Insomniacs
Number of subjects: 11

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 11
Study: 9848758

Group type: EXPERIMENTAL
Intervention: Endotracheal continuous positive airway pressure (ETCPAP) after rescue surfactant therapy
Number of subjects: 46
Study: 7815711

Group type: EXPERIMENTAL
Intervention: Pipecuronium bromide 0.04 mg.kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vecuronium bromide 0.08 mg.kg‐1
Number of subjects: 50
Study: 2805024

Group type: EXPERIMENTAL
Intervention: Cisapride, 0.1 to 0.2 mg/kg three times daily for up to four weeks
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 15357108

Group type: EXPERIMENTAL
Intervention: Plasma levels of TNF-alpha and IL-6 in patients with moderate/severe CHF (group 3)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: NYHA functional class (FC)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Plasma TNF-alpha
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Plasma IL-6
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic pressure
Number of subjects: 118
Study: 30586724

Group type: EXPERIMENTAL
Intervention: BP-SES (biodegradable polymer-based sirolimus-eluting stents)
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: PP-EES (permanent polymer-based everolimus-eluting stents)
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: PP-SES (early generation permanent polymer-based sirolimus-eluting stents)
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: PP-EES
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: PP-SES
Number of subjects: 2603
Study: 28155569

Group type: EXPERIMENTAL
Intervention: Subtenon drug delivery of demethylvancomycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subconjunctival injection of demethylvancomycin
Number of subjects: 60
Study: 26148018

Group type: EXPERIMENTAL
Intervention: Gluten-casein supplementation for 7 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 74
Study: 22857983

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD)
Number of subjects: 852

Group type: COMPARATOR
Intervention: Continuous androgen deprivation (CAD)
Number of subjects: 852
Study: 21595543

Group type: EXPERIMENTAL
Intervention: Traditional Japanese massage therapy (40‐minute full-body massage)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (40‐minute rest without massage)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Traditional Japanese massage therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2
Study: 18494201

Group type: EXPERIMENTAL
Intervention: Postoperative blood salvage system (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard suction collection without blood salvage system (Group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative collected autotransfusion blood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative collected autologous blood and allogeneic blood
Number of subjects: 0
Study: 16569875

Group type: EXPERIMENTAL
Intervention: Norfloxacin (NOR)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pivmecillinam (PIV)
Number of subjects: 19
Study: 12657355

Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10718828

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8937799

Group type: EXPERIMENTAL
Intervention: Heating and peak temperature conditions for full-term infants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heating and cooling stages for preterm infants
Number of subjects: 20
Study: 1389281

Group type: EXPERIMENTAL
Intervention: Centrifugal pump (Biomedicus)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Roller pump (Stöckert)
Number of subjects: 50
Study: 2988845

Group type: EXPERIMENTAL
Intervention: 15% Butylated hydroxytoluene (BHT) in mineral oil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo mineral oil vehicle
Number of subjects: 30
Study: 29787482

Group type: EXPERIMENTAL
Intervention: High physical activity (PA)
Number of subjects: 913

Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 913

Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 913
Study: 27340947

Group type: EXPERIMENTAL
Intervention: External focus instructions on the swing of the club
Number of subjects: 60

Group type: COMPARATOR
Intervention: Internal focus instructions on the swing of the arm
Number of subjects: 60
Study: 25175994

Group type: EXPERIMENTAL
Intervention: High stress condition
Number of subjects: 129

Group type: COMPARATOR
Intervention: Low stress condition
Number of subjects: 129